Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vapendavir DDI with Midazolam in Healthy Volunteers
NCT02204501Phase 1Completed
- Sponsor
- Biota Holdings Limited
- Start
- May 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Vapendavir in human rhinovirus infection (2 arms), sponsored by Biota Holdings Limited. Primary endpoint: Effect of Vapendavir on the PK Profile of Midazolam at Day 12. Started May 2014; status: completed.
02
Drugs
Vapendavir
03
Conditions
human rhinovirus infection
Beyond the preview
Go deeper on NCT02204501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02204501.